Patient Reported Outcomes in Metastatic Breast Cancer Studies: Evaluating the Impact of the FDA Guidance for Industry
Introduction: Over the last two decades, a number of new therapies have demonstrated improved overall survival in metastatic breast cancer (MBC) [10]. Despite these advances, MBC remains incurable with a median survival of less than three years [7, 10, 11, 15]. Prolonging survival and maintaining qu...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Levy Library Press
2019-04-01
|
| Series: | Journal of Scientific Innovation in Medicine |
| Subjects: | |
| Online Access: | https://journalofscientificinnovationinmedicine.org/articles/11 |